Drug Details
| General Information of the Drug (ID: DR4274) | ||||
|---|---|---|---|---|
| Name |
Recombinant vaccinia Neu vaccine
|
|||
| Molecular Type |
Vaccine
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Infiltration of CD4+/CD8+ T lymphocytes | ||||
| In-vivo Model | 6 to 8 weeks old BALB-neuT mice were subcutaneously inoculated in the right flank with 0.2 mL Phosphate-buffered saline (PBS) containing 1*106 SALTO-5 cells. | |||||
| Experimental
Result(s) |
Combined rV-neuT+CUR treatment was more effective at reducing tumor growth and increasing mouse survival, anti-Neu humoral response, and IFN-gamma/IL-2 T-cell release in vitro than the individual treatment. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | HIV Protease (HIV PR) | Molecule Info | [3] | |
